Correlation Between Opthea and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Opthea and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Opthea and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Opthea and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on Opthea and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Opthea with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Opthea and Acrivon Therapeutics,.

Diversification Opportunities for Opthea and Acrivon Therapeutics,

-0.05

Correlation Coefficient

Opthea  Acrivon Therapeutics,

Good diversification

The 3 months correlation between Opthea and Acrivon is -0.05. Overlapping area represents the amount of risk that can be diversified away by holding Opthea and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and Opthea is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Opthea are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of Opthea i.e., Opthea and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between Opthea and Acrivon Therapeutics,

Considering the 90-day investment horizon Opthea is expected to generate 0.76 times more return on investment than Acrivon Therapeutics,. However, Opthea is 1.32 times less risky than Acrivon Therapeutics,. It trades about 0.0 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.11 per unit of risk. If you would invest  387.00  in Opthea on December 28, 2024 and sell it today you would lose (46.00) from holding Opthea or give up 11.89% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	88.52%
Values	Daily Returns

Opthea  vs.  Acrivon Therapeutics, Common

Opthea

Risk-Adjusted Performance

Very Weak

Over the last 90 days Opthea has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Opthea is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.

Acrivon Therapeutics,

Risk-Adjusted Performance

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly stable which may send shares a bit higher in April 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.

Pair Trading with Opthea and Acrivon Therapeutics,

The main advantage of trading using opposite Opthea and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Opthea position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind Opthea and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.